IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
At Cambrex, we offer a tried and trusted approach to technology transfer, for scale-up or when transitioning to a different facility.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
We can support you, at any size or stage, with a range of primary and secondary packaging solutions.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
East Rutherford, NJ – March 27, 2018 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it had been recognized across six categories in the annual CMO (Contract Manufacturing Organization) Leadership Awards, which were announced at a ceremony in New York, on March 21.
Cambrex was recognized in the following categories: capabilities, compatibility, service, expertise, quality and reliability; and were noted for individual attribute awards for accessible senior management, innovation, on-time reputation, right first time, state-of-the-art, and strength of science. This award represents Cambrex’s 4th consecutive successful year in these awards, following honors in 2015, 2016 and 2017.
“The awards are in recognition of the highest level of accomplishment that drug development and manufacturing organizations have attained in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “They are especially meaningful because recipients are only evaluated by the customers they have actually worked with, and include the six critical categories of capabilities, compatibility, expertise, quality, reliability and service. An award in any of these categories adds to the distinction and reputation of CMOs throughout the global drug discovery, development, manufacturing and marketing industries.”
“We are once again honored to be recognized by our industry peers and customers in the CMO Leadership Awards,” commented Steven M. Klosk, President and Chief Executive Officer at Cambrex. He added, “We continue to invest in the right people, technologies and capacity to meet our customers’ and the pharmaceutical industry’s needs, and it is extremely gratifying to be acknowledged for our ongoing accomplishments.”
Established in 2011, the CMO Leadership Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing. The awards are presented by Life Science Leader magazine and Industry Standard Research.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing.
For more information, please visit www.cambrex.com
Thank you for subscribing up to our newsletter.